We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions
News

Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions

Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions
News

Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Prokarium Ltd has completed a key technology acquisition from Emergent BioSolutions Inc., a global biopharmaceutical company based in Maryland, USA.

The technology includes Emergent’s live Salmonella-based typhoid vaccine Typhella™ and its genetic technology spi-VEC™.

Prokarium will combine Typhella™ and spi-VEC™ with its proprietary genetic and formulation technologies to form Vaxonella™, a versatile oral vaccine delivery platform.

Emergent has successfully conducted several phase 1 and 2 clinical trials, which have shown Typhella™ to be safe and immunogenic as a typhoid vaccine.

The combination with Prokarium’s plasmid stabilization technology ORT-VAC™, will enable the delivery of recombinant protein vaccines without needles or adjuvants.

Prokarium plans to offer this Vaxonella™ platform to the biotech community on a licensing basis.

Prokarium will focus on the development of a dual oral vaccine against typhoid and ETEC (enterotoxigenic E. coli - a major cause of diarrhoea) for travellers and developing country markets.

There are 22 million cases of typhoid every year resulting in 200,000 deaths, so an effective oral vaccine could have a significant impact.

Currently there is no dedicated vaccine against ETEC, considered responsible for 300,000 - 500,000 deaths per year, mostly of young children.

Dr Rocky Cranenburgh, Prokarium’s Chief Scientific Officer, said “I am delighted with the acquisition of this technology from Emergent; the combination of their Salmonella vector with Prokarium’s technologies allows us to develop an advanced oral delivery platform which gives Prokarium the potential to revolutionize vaccinations”.

Advertisement